Inmune Bio (INMB) Non-Current Assets (2017 - 2026)
Inmune Bio (INMB) posted Non-Current Assets of $3.0 million for Q1 2026, up 21.59% sequentially from $2.5 million in Q4 2025, and down 82.21% YoY from $16.8 million in Q1 2025.
Inmune Bio (INMB) Non-Current Assets (2017 - 2026) Analysis & Trends
Inmune Bio has reported Non-Current Assets for 10 years, with the latest figure at $3.0 million in Q1 2026.
- Quarterly Non-Current Assets fell 82.21% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.9 million (down 141.23% YoY) and the FY2025 annual result came in at $2.5 million, down 85.42% from the prior year.
- Non-Current Assets grew to $3.0 million in Q1 2026 per INMB's latest filing, from $2.5 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $17.3 million in Q1 2022 and troughed at -$36.0 million in Q2 2025.
- A 5-year average of $11.4 million and a median of $17.0 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets advanced 3.8% in 2022, then tumbled 312.49% in 2025.
- Over 5 years, Non-Current Assets stood at $17.1 million in 2022, then declined by 0.36% to $17.1 million in 2023, then fell by 0.93% to $16.9 million in 2024, then slumped by 85.42% to $2.5 million in 2025, then increased by 21.59% to $3.0 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $3.0 million, $2.5 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | 3.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.05 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Dec 31, 2025 | 2.46 Mn |
| Sep 30, 2025 | 2.69 Mn |
| Jun 30, 2025 | -36.03 Mn |
| Mar 31, 2025 | 16.84 Mn |
| Dec 31, 2024 | 16.90 Mn |
| Sep 30, 2024 | 16.93 Mn |
| Jun 30, 2024 | 16.96 Mn |
| Mar 31, 2024 | 17.01 Mn |
| Dec 31, 2023 | 17.06 Mn |
| Sep 30, 2023 | 17.09 Mn |
| Jun 30, 2023 | 17.11 Mn |
| Mar 31, 2023 | 17.10 Mn |
| Dec 31, 2022 | 17.12 Mn |
| Sep 30, 2022 | 17.14 Mn |
| Jun 30, 2022 | 17.26 Mn |
| Mar 31, 2022 | 17.29 Mn |
| Dec 31, 2021 | 17.34 Mn |
| Sep 30, 2021 | 16.74 Mn |